

Research Article

A Comparative Study Between Tranexamic Acid And Epsilon-Amino-Caproic Acid (EACA) In Reducing Post-Operative Bleeding In Patients Undergoing on Pump Coronary Artery Bypass Grafting (CABG) Surgeries

Dr Satish Kumar Mishra¹, Dr Gobind Ji Thakur², Dr Rajeev Nair³ and Dr Veena MN^{*4}¹MD,DM Cardiac Anesthesia Department of Anaesthesiology and critical care Command hospital Air force Bangalore, India²Mch CTVS, Army Hospital R&R Delhi department of CTVS, India³MD Anesthesia, HOD, Department of Anaesthesiology and critical care Command hospital airforce Bangalore, India⁴MD, Pharmacology, Assistant Professor, Department of Clinical Pharmacology, KVG Medical College Sullia Karnataka, India**Article History**

Received: 13.02.2020

Revision: 18:04:2020

Accepted: 25.05.2020

Published: 07.06.2020

Journal homepage:<https://www.easpublisher.com/easjacc>**Quick Response Code**

Abstract: Background: The amount of strain that cardiac surgery exerts on blood bank services is an example that emphasises the need for multimodal blood conservation strategy. The most common factor which is being attributable to increase bleeding after cardiac surgery is hyperfibrinolysis. Therefore the use of antifibrinolytics during high risk cardiac surgery becomes inevitable. Commonly used antifibrinolytic include Tranexamic Acid(TA) and Epsilon-amino-caproic acid (EACA) .The aim of our study was to compare the effectiveness of both TA and EACA in reducing post-surgical bleeding in on-pump CABG surgeries and to assess the post-operative complications associated with its use. **Material and Methods:** After obtaining informed written consent, approval of ethics and research committee patients who were scheduled for on-pump CABG were included in the study. Patients were divided into two groups randomly by using a computer generated randomized block design namely group TA(n=40) and group EACA (n=40). TA group received tranaxamic acid at a dose of 10mg/kg IV over 20 min at the time of induction then 1-2 mg/kg in CPB prime followed by 1 mg /kg/hr infusion during surgery. Group EACA received EACA in a dose of 100mg/kg/IV over 20 min at the time of induction then 5-10mg/kg in CPB prime followed by 10mg/kg/hr. infusion during surgery. Patients were assessed for blood loss and were monitored for fibrinogen level and D- dimer levels. Other parameters which were assessed included Re-exploration and post-operative complications. **Result:** Primary outcomes like bleeding at 4hrs, there was no significant difference between the groups but when total bleeding at 24hrs. was compared there was a significantly lesser bleed in group TA group compared to group EACA (P=0.0022).The requirement of PRBC in group TA was for 3 patients, where as in EACA group 4 patients required PRBC (P>0.05).There was no significant difference in the rate of post-operative complications between the groups.(P>0.05) .**Conclusion :** Our study showed that TA is more effective when compared to EACA in inhibiting fibrinolysis during on pump CABG surgery and thus results in decreased post-operative bleeding. Our study also re-emphasized the fact that neither of the drug led to any additional risk of post-operative thrombotic complications.

Keywords: TA : Tranexamic Acid, EACA : Epsilon-amino-caproic acid , CPB: Cardio Pulmonary Bypass, PRBC: Packed Red Blood Cell,FFP: Fresh Frozen Plasma.

Copyright © 2020 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution **4.0 International License (CC BY-NC 4.0)** which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

For decades the most common indication for blood transfusion is perioperative bleeding and cardiac surgery ranks high on the list. The reason which is being attributable to this complication is the institution of Cardio Pulmonary Bypass (CPB). CPB leads to series of events like compliment activation, platelet Activation and increased fibrinolysis which contributes to increase post-operative bleeding (Paparella, D. *et al.*, 2006). Post-operative bleeding in itself carries a high

risk for in hospital mortality. Cardiac surgical pateints who are taken up for re explorartion due to bleeding carry a fourfold increase in mortality and sternal wound infection (Bridges, C. R. 2007). Therefore a multimodal approach is recommended to reduce perioperative bleeding which includes the use of anti fibrinolytic agents.

Anti fibrinolytic agents have been used during cardiac surgery to reduce the risk of post-operative bleeding. Most commonly used antifibrinolytic agents

include Aprotinin and lysine analogs (Tranexamic acid TA and E- amino caproic acid EACA).

Aprotinin is a serine protease inhibitor which inhibits multiple proteases like plasmin, kallikrein, trypsin, and activated factor XII, thereby reducing blood loss. In 2007 a prospective study on high risk patients undergoing cardiac surgery known as Blood conservation using Antifibrinolytics in a Randomized Trial (BART) reported an increased mortality with use of aprotinin compared to lysine analogs (Fergusson, D. A. *et al.*, 2008). Later due to warning from Food and Drug administration (FDA), Bayer health care withdrew apportioning from the market. Now the Society of Thoracic Surgeons (STS) guidelines (Ferraris, V. A. *et al.*, 2011) recommend the use of anti-fibrinolytic agents (only lysine analogues), as a strategy to reduce perioperative blood loss during cardiac surgery.

Tranexamic acid (TA) is a synthetic antifibrinolytic that blocks lysine binding site on plasminogen molecule, thus inhibiting the interaction with plasmin and fibrin which leads to decreased post-operative bleeding (Mehr-Aein, A. *et al.*, 2007; & Greilich, P. E. *et al.*, 2009). Similarly EACA is a synthetic lysin analog which reduces the rate of plasmin formation and further decreases the degradation of fibrin to fibrin degradation product (FDP) (Sterns, L. P. 1967). Apart from this EACA also has a platelet sparing action which leads to inhibition of plasmin mediated platelet injury (Slaughter, T. F. *et al.*, 1997).

Both TA and EACA have been shown to decrease post-operative bleeding associated with CPB. However there are no large studies comparing the effectiveness of both drugs in patients undergoing on pump CABG surgeries.

The aim of our study was to compare the effectiveness of both TA and EACA in reducing post-surgical bleeding in on-pump CABG surgeries with regards to the amount of blood loss at 4 hrs and 24 hrs as the primary outcome. The secondary outcome of our study included the rate of transfusion of packed red blood cell (PRBC), fresh frozen plasma (FFP) and platelets. Other parameters which were assessed included re exploration rates and post-operative complications.

MATERIAL AND METHODS

After obtaining informed written consent, approval of ethics and research committee patients who were scheduled for on-pump CABG were included in

the study. This study was carried out between June 2019 to Feb 2020 at a tertiary care teaching hospital. Patients with concomitant valvular heart disease, recent Myocardial Infarction (MI < 4 wks) Ejection Fraction < 40%, Pre-existing neurological, pulmonary or hepatic dysfunction were excluded from the study.

Patients were divided into two groups randomly by using a computer generated randomized block design namely group TA (n=40) and group EACA (n=40). In both the group under strict aseptic precaution under local anaesthesia a wide bore peripheral IV cannula, right radial artery cannulation and right femoral artery cannulation was done for continuous hemodynamic monitoring. Anaesthesia was induced with Inj etomidate (0.2mg/kg), Inj Fentanyl (3-5 ug/kg) and Inj Rocuronium (0.8-1mg /Kg). After induction of anaesthesia right internal jugular vein cannulation was done with 7.5 Fr Triple lumen catheter and PA catheter was inserted. Anaesthesia was maintained with air and oxygen (50%), sevoflurane (1-3%) and Inj Atracurium (0.5-1mg/Kg). After sternotomy and heparinization CPB was established once ACT was >420 Sec.

TA group received tranexamic acid at a dose of 10mg/kg IV over 20 min at the time of induction then 1-2 mg/kg in CPB prime followed by 1 mg/kg/hr infusion during surgery. Group EACA received EACA in a dose of 100mg/kg/IV over 20 min at the time of induction then 5-10mg/kg in CPB prime followed by 10mg/kg/hr infusion during surgery. Later Inj Protamine was administered to reverse the effect of Heparin.

After completion of surgery patients were shifted to ICU and were assessed for blood loss at 4 hrs and 24 hrs. Indication for transfusion of PRBC was when haemoglobin levels were less than 8gm/dl. FFP was transfused if post-operative drain was more than 250ml/hr in first hour. Platelet transfusion was indicated if platelet counts were less than 50000/mm³. The degree of fibrinolysis was measured by Thromboelastography (TEG), (Hemostasis system, Haemoscope corporation USA)

Other parameters which were monitored included fibrinogen level and D- dimer levels at 4 hrs and 24 hrs. Re-exploration of case was considered if the bleeding was > 300ml/hr in first 2hrs. or if >200 ml/hr. for 4 consecutive hrs, with normal coagulation data. Patients were also observed for post-operative complications like MI, Stroke, Deep vein thrombosis (DVT), renal dysfunction and seizures for 72 hrs.




Figure 1: Flow diagram depicting activation of coagulation and fibrinolytic activities during cardiac surgery. PKK -Pre kallikrein; HMWK -High molecular weight kininogen; tPA -Tissue plasminogen activator; FDPs -Fibrin degradation products

Table 1. Baseline Demography

Parameter	Group TA (n=40)	Group EACA(n=40)	P
Age(Yrs)	68 ± 2	67 ± 3	0.967
Weight(Kg)	74 ± 3	76 ± 4	0.271
Height(Cm)	165 ± 3	162 ± 6	0.118
M/F(Gender)	26/14	28/12	0.739

TA= Tranexamic Acid EACA= Epsilon-amino-caproic-acid

Table 2. Intra operative time and intervention

Variables	Group TA (n=40)	Group EACA(n=40)	P
Cross Clamp Time>50 min	10(25%)	10(25%)	1
CPB>70 min	14(35%)	15(37.5%)	0.793

Table 3. Primary and secondary Outcome

Parameter	Group TA(n=40)	Group EACA(n=40)	P
Bleeding at 4hrs(ml)	190(90-260)	210(110-320)	0.0321
Total Bleeding at 24 hrs(ml)	360(140-530)	440(170-740)	0.0022
PRBC Transfused	3	2	0.921
FFP Transfused	1	1	1
Platelet Transfused	1	1	1
Re Exploration	0	0	1

PRBC: Packed Red Blood Cell, FFP: Fresh Frozen Plasma**Table 4. Post-operative Complications**

Parameters	Group TA (n=40)	Group EACA(n=40)	P
MI	0	1	0.981
Stroke	1	1	1
Seizure	1	0	0.981
PE	0	0	-
DVT	0	0	-
Doubling of S.Cr	0	1	0.981

MI: Myocardial Infarction **DVT:** Deep Vein Thrombosis **PE:** Pulmonary Embolism **S. Cr:** Serum Creatinine.

Statistical analysis was done with SPSS software version 19.0 normality of the test were checked using Kolmogorov-smirnov test. The values which were obtained were analyzed and were expressed as mean \pm Standard Deviation (SD) and median \pm range. For continuous variables for parametric data, Independent's test were used and for non-parametric data Mann-Whitney u test were used. For categorical data, Chi-Square test or fisher's exact test were used. A P Value of <0.05 was considered to be statistically significant.

RESULT

Demographic variables like age, weight, height, male-female ratio were comparable in both groups. (Table-1) The cross clamp time & duration on CPB were also comparable in both groups (Table-2). Primary outcomes like bleeding at 4hrs, there was no significant difference between the groups, group TA 190(90-260)ml versus group EACA210(110-320)ml ($p=0.032$) but when total bleeding at 24 hrs was compared there was a significantly lesser bleed in group TA 360(140-530)ml compared to group EACA 440(170-740)($P=0.0022$).

The requirement of PRBC in group TA was for 3 patients, where as in EACA group 4 patients required PRBC ($P>0.05$). One patient in each group required FFP transfusion ($P>0.05$). Both the groups did not require any platelet transfusion & the transfusion rate was non-significant between the groups. Both the groups had no re exploration due to excessive bleeding.(Table-3).

There was no significant difference in the rate of post-operative complications between the groups.($P>0.05$) (Table-4)

DISCUSSION

On pump CABG is associated with increased risk of post-operative bleeding compared to OPCAB (Wei, M. *et al.*, 2006; & Abu-Omar, Y., & Taggart, D. P. 2009) reason best attributable to use of CPB, which is associated with increased fibrinolysis & increased

concentration of inflammatory mediators, which has urged researchers all around the world to investigate the probable role of anti fibrinolytics in on pump cardiac surgeries (Mariani, M. A. *et al.*, 1999).

In our study we found that there was no significant difference in the amount of post-operative bleeding at 4 hours between the groups however at 24 hrs there was a significant difference between both the groups with lesser bleeding in group TA compared to group EACA. This may be due to the fact the TA is 10 times more potent than EACA (Dhir, A. 2013). Similar findings were obtained in a study comparing TA & EACA with placebo conducted by Karski Karski, J. M. *et al.*, (1993).

Chauhan, S. *et al.*, (2004) & Falana, O., & Patel, G. (2014) while comparing both the drugs showed that there was no significant difference in the rate of post-operative transfusion of PRBC, FFP / Platelet or the rate of re-exploration for excessive bleeding, which was comparable with our study.

Post-operative blood transfusion after CABG is associated with increased long term mortality (Engoren, M. C. *et al.*, 2002). Therefore the role of these drugs in reducing the transfusion rate after on pump CABG is very significant. There were no difference in the rate of post-operative complication's between the group's. Hardy *Et al.*, in his study while comparing both the drugs did not find any significant difference between the drugs with regards to post-operative thrombo embolic complications (Hardy, J. F. *et al.*, 1998).

The Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial (Myles, P. S. *et al.*, 2017) compared TA with placebo in patients undergoing coronary bypass surgery and demonstrated that patients who were randomly assigned to TA therapy had a significantly reduced risk for reoperations due to postoperative bleeding, as well as a decreased need for transfusion of any blood products. Based on these data, all the transfusion guidelines support the use

of antifibrinolytic agents in patients undergoing cardiac surgery with CPB (Ferraris, V. A. *et al.*, 2011).

There are controversies with regards to the dosing of the drug. A high dose (20mg/kg) TA is associated with increased risk of post-operative seizures and therefore a low dose (10mg/kg) regime is recommended (Manji, R. A. *et al.*, 2012). Armelin *et al.*, compared the low dose and high dose TA regimen and found no difference with respect to amount of post-operative blood loss or transfusion requirement (Armellin, G. *et al.*, 2004). In our study we used low dose TA dosing and did not find any significant post-operative complications.

CONCLUSION

Based on the results of our study it can be concluded that both TA & EACA effectively inhibit fibrinolysis during on pump CABG surgery and thus results in decreased post-operative bleeding. When compared between the two, TA was slightly better with respect to post-operative bleeding at 24hrs.

Fibrinolytic system plays an important role in maintaining the vascular patency and thus the vascular haemostasis. After institution of CPB there is extensive tissue injury and the equilibrium shifts leading to increased fibrinolysis which contributes to bleeding and coagulopathy. Therefore a comprehensive approach to blood conservation during cardiac surgery is highly recommended including use of antifibrinolytic agents.

The use of antifibrinolytic agents must be governed by an view of their inherent risks and benefits. Even after extensive research it is still very difficult to predict whether any given patient is at increased risk for bleeding or thrombosis. Antifibrinolytic therapy must be used when hyper fibrinolysis occurs and it seems attractive to have point-of-care fibrinolysis monitoring to guide the therapy. In an ideal world, it will also be nice to know the genetic variants for fibrinolysis or prothrombotic states, as some patients may not require any agent.

Our study also re-emphasized the fact that neither of the drug led to any additional risk of post-operative thrombotic complications & thus can potentially become a standard of care for blood conservation in patients undergoing on pump CABG.

REFERENCES

1. Abu-Omar, Y., & Taggart, D. P. (2009). The present status of off-pump coronary artery bypass grafting. *European journal of cardio-thoracic surgery*, 36(2), 312-321.
2. Armellin, G., Vinciguerra, A., Bonato, R., Pittarello, D., & Giron, G. P. (2004). Tranexamic acid in primary CABG surgery: high vs low dose. *Minerva anesthesiologica*, 70(3), 97-107.
3. Bridges, C. R. (2007). Valid comparisons of antifibrinolytic agents used in cardiac surgery.
4. Chauhan, S., Gharde, P., Bisoi, A., Kale, S., & Kiran, U. (2004). A comparison of aminocaproic acid and tranexamic acid in adult cardiac surgery. *Annals of cardiac anaesthesia*, 7(1), 40-43.
5. Dhir, A. (2013). Antifibrinolytics in cardiac surgery. *Annals of cardiac anaesthesia*, 16(2), 117.
6. Engoren, M. C., Habib, R. H., Zacharias, A., Schwann, T. A., Riordan, C. J., & Durham, S. J. (2002). Effect of blood transfusion on long-term survival after cardiac operation. *The Annals of thoracic surgery*, 74(4), 1180-1186.
7. Falana, O., & Patel, G. (2014). Efficacy and safety of tranexamic acid versus ϵ -aminocaproic acid in cardiovascular surgery. *Annals of Pharmacotherapy*, 48(12), 1563-1569.
8. Fergusson, D. A., Hébert, P. C., Mazer, C. D., Fremes, S., MacAdams, C., Murkin, J. M., ... & Bussières, J. S. (2008). A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *New England Journal of Medicine*, 358(22), 2319-2331.
9. Ferraris, V. A., Brown, J. R., Despotis, G. J., Hammon, J. W., Reece, T. B., Saha, S. P., ... & Mazer, C. D. (2011). 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. *The Annals of thoracic surgery*, 91(3), 944-982.
10. Ferraris, V. A., Brown, J. R., Despotis, G. J., Hammon, J. W., Reece, T. B., Saha, S. P., ... & Mazer, C. D. (2011). 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. *The Annals of thoracic surgery*, 91(3), 944-982.
11. Greilich, P. E., Jessen, M. E., Satyanarayana, N., Whitten, C. W., Nuttall, G. A., Beckham, J. M., ... & Butterworth, J. F. (2009). The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. *Anesthesia & Analgesia*, 109(1), 15-24.
12. Hardy, J. F., Bélisle, S., Robitaille, D., RT, M. R., & RT, L. G. (1998). Prophylactic tranexamic acid and ϵ -aminocaproic acid for primary myocardial revascularization. *The Annals of thoracic surgery*, 65(2), 371-376.
13. Karski, J. M., Teasdale, S. J., Norman, P. H., Carroll, J. A., Weisel, R. D., & Glynn, M. F. X. (1993). Prevention of postbypass bleeding with tranexamic acid and ϵ -aminocaproic acid. *Journal of cardiothoracic and vascular anesthesia*, 7(4), 431-435.
14. Manji, R. A., Grocott, H. P., Leake, J., Ariano, R. E., Manji, J. S., Menkis, A. H., & Jacobsohn, E. (2012). Seizures following cardiac surgery: the

- impact of tranexamic acid and other risk factors. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*, 59(1), 6-13.
15. Mariani, M. A., Gu, Y. J., Boonstra, P. W., Grandjean, J. G., van Oeveren, W., & Ebels, T. (1999). Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate?. *The Annals of thoracic surgery*, 67(5), 1370-1375.
 16. Mehr-Aein, A., Sadeghi, M., & Madani-civi, M. (2007). Does tranexamic acid reduce blood loss in off-pump coronary artery bypass?. *Asian Cardiovascular and Thoracic Annals*, 15(4), 285-289
 17. Myles, P. S., Smith, J. A., Forbes, A., Silbert, B., Jayarajah, M., Painter, T., ... & Wallace, S. (2017). ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. *N Engl J Med*. 376, 136–148.
 18. Paparella, D., Galeone, A., Venneri, M. T., Coviello, M., Scrascia, G., Marraudino, N., ... & Brister, S. J. (2006). Activation of the coagulation system during coronary artery bypass grafting: comparison between on-pump and off-pump techniques. *The Journal of thoracic and cardiovascular surgery*, 131(2), 290-297.
 19. Slaughter, T. F., Faghih, F., Greenberg, C. S., Leslie, J. B., & Sladen, R. N. (1997). The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. *Anesthesia & Analgesia*, 85(6), 1221-1226.
 20. Sterns, L. P. (1967). Lillehei CW: Effect of epsilon aminocaproic acid upon blood loss following open-heart surgery: an analysis of 340 patients. *Canadian journal of surgery. Journal canadien de chirurgie*, 10(3), 304-307.
 21. Wei, M., Jian, K., Guo, Z., Wang, L., Jiang, D., Zhang, L., & Tarkka, M. (2006). Tranexamic acid reduces postoperative bleeding in off-pump coronary artery bypass grafting. *Scandinavian Cardiovascular Journal*, 40(2), 105-109.